Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 11/20 | 1.00 |
| ▸ | IGF1R | P08069 | 11/20 | 0.88 |
| ▸ | EGFR | P00533 | 2/20 | 0.78 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.78 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.76 |
| ▸ | AURKA | O14965 | 1/20 | 0.74 |
| ▸ | LCK | P06239 | 1/20 | 0.74 |
| ▸ | BRAF | P15056 | 1/20 | 0.74 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.74 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310596 | 0.95 | INSR (0.91) | INSRIGF1REGFRERBB2MAPK14 | |
| SCHEMBL10290730 | 0.95 | INSR (0.90) | INSRIGF1REGFRERBB2MAPK14 | |
| SCHEMBL310654 | 0.94 | IGF1R (0.90) | INSRIGF1REGFRERBB2MAPK14 | |
| SCHEMBL310147 | 0.94 | IGF1R (1.00) | INSRIGF1REGFRERBB2MAPK14 | |
| SCHEMBL311366 | 0.94 | EGFR (0.89) | INSRIGF1REGFRERBB2MAPK14 | |
| SCHEMBL311287 | 0.92 | INSR (0.90) | INSRIGF1REGFRERBB2MAPK14 | |
| SCHEMBL311086 | 0.92 | INSR (0.89) | INSRIGF1REGFRERBB2MAPK14 | |
| SCHEMBL325010 | 0.92 | INSR (1.00) | INSRIGF1REGFRERBB2MAPK14 | |
| SCHEMBL309948 | 0.91 | IGF1R (0.89) | INSRIGF1REGFRERBB2MAPK14 | |
| SCHEMBL310321 | 0.90 | INSR (0.94) | INSRIGF1REGFRERBB2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| EP-2162454-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | INSR 814/4885IGF1R 633/4885EGFR 491/4885 |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | INSR 814/4885IGF1R 633/4885EGFR 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.